Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ContraFect Corporation (Nasdaq: CFRX) announced the dosing of the first patient in its Phase 1b/2 clinical study of exebacase for chronic prosthetic joint infections (PJI) due to Staphylococcus aureus or Coagulase-Negative Staphylococci. This randomized, double-blind, placebo-controlled study aims to evaluate the safety, pharmacokinetics, and efficacy of exebacase administered intra-articularly during a DAIR procedure. The study will be conducted in two parts over up to two years, with an early efficacy assessment at six weeks. ContraFect’s CEO emphasized the potential of exebacase to replace current surgical treatments and improve patients' quality of life by eradicating infections that have seen little improvement in clinical outcomes.
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotech company, has reported significant data on CF-370, demonstrating its efficacy against an extensively drug-resistant (XDR) strain of Pseudomonas aeruginosa in a neutropenic rabbit pneumonia model. These findings were presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in April 2023. CF-370 exhibited notable antibacterial activity, significantly reducing bacterial density, especially when combined with amikacin. The mechanism of CF-370 involves rapid cell wall destabilization, providing hope for patients with life-threatening infections. The company's focus on addressing antibiotic resistance is underscored by the alarming mortality rates associated with such infections, which can reach 60% in patients suffering from HAP/VAP.